Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

卵巢癌的分子流行病学：澳大利亚卵巢癌研究国家临床随访核心

• 批准号: nhmrc : 400281
• 负责人: A/Pr Margaret Davy
• 金额: $ 58.89万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/molecular-epidemiology-ovarian-up-core/95727
• 关键词: Molecular; Epidemiology; Ovarian; Cancer; Australian

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 new cases diagnosed and 750 deaths each year. There is an urgent need to better understand the molecular, epidemiological and genetic characteristics of epithelial ovarian cancer and how these influence response to treatment and clinical outcome. Ovarian cancer is a histologically and clinically diverse disease and the variability in clinical outcome in ovarian cancer patients suggests that reliable predictive factors would be of clinical value. However, it is clear that the collection of hundreds of annotated biospecimens is essential if the interaction of genes and environment in the genesis of this disease is to be understood or the molecular features of this disease dissected. Recognizing that this can only be achieved through large-scale collaboration, the Australian Ovarian Cancer Study (AOCS) was established in 2000 by scientists from the Peter MacCallum Cancer Centre, the Queensland Institute for Medical Research, Melbourne University and Westmead Institute for Cancer Research in collaboration with clinicians across Australia. AOCS has recruited 1105 patients to date and this Research Proposal aims to complete the collection of clinical data on all AOCS patients nationally, to validate the use of microarray gene expression profiles to predict clinical outcome and to find genetic variants that may determine clinical outcome in individual patients. The creation of AOCS has provided a unique oportunity to collect one of the finest ovarian cancer biological sample sets in the world. We believe that this internationally significant study will shed light on the basis of response of ovarian cancer to treatment and provide an ongoing resource for research into the causes of ovarian cancer, and studies on the response to treatment.

卵巢癌是澳大利亚妇女第七常见的癌症，也是第五常见的癌症死亡原因，每年约有1200例新诊断病例和750例死亡。迫切需要更好地了解上皮性卵巢癌的分子、流行病学和遗传学特征，以及这些特征如何影响治疗反应和临床结果。卵巢癌是一种组织学和临床上多样化的疾病，卵巢癌患者临床结局的变异性表明可靠的预测因素具有临床价值。然而，很明显，如果要了解这种疾病发生中基因和环境的相互作用或解剖这种疾病的分子特征，收集数百个注释的生物标本是必不可少的。认识到这只能通过大规模合作才能实现，澳大利亚卵巢癌研究（AOCS）于2000年由Peter MacCallum癌症中心，昆士兰州医学研究所，墨尔本大学和Westmead癌症研究所的科学家与澳大利亚各地的临床医生合作建立。迄今为止，AOCS已招募了1105名患者，本研究提案旨在完成全国所有AOCS患者的临床数据收集，以验证微阵列基因表达谱的使用，以预测临床结果，并找到可能决定个体患者临床结果的遗传变异。AOCS的创建为收集世界上最好的卵巢癌生物样本集之一提供了独特的机会。我们相信，这项具有国际意义的研究将阐明卵巢癌对治疗的反应，并为研究卵巢癌的病因和对治疗的反应提供持续的资源。